Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, „The Lancet”, 396 (10255), 2020, s. 887–897, DOI: 10.1016/S0140-6736(20)31866-3, PMID: 32896291, PMCID: PMC7471804 [dostęp 2021-04-01].
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, „The Lancet”, 396 (10255), 2020, s. 887–897, DOI: 10.1016/S0140-6736(20)31866-3, PMID: 32896291, PMCID: PMC7471804 [dostęp 2021-04-01].
